Navidea Biopharmaceuticals, Inc. (NAVB)
Stock Price:
$2.82 USD
-0.64 (-18.50%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
71.76M |
| Revenue (ttm) |
772,474 |
| Net Income (ttm) |
-11.19M |
| Shares Out |
25.45M |
| EPS (ttm) |
-0.66 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 11, 2020 |
| Last Price |
$2.82 |
| Previous Close |
$3.46 |
| Change ($) |
-0.64 |
| Change (%) |
-18.50% |
| Day's Open |
3.62 |
| Day's Range |
2.76 - 3.69 |
| Day's Volume |
1,092,694 |
| 52-Week Range |
0.49 - 5.36 |
More Stats
| Market Cap |
71.76M |
| Enterprise Value |
72.11M |
| Earnings Date (est) |
Aug 13, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
25.45M |
| Float |
14.70M |
| EPS (basic) |
-0.68 |
| EPS (diluted) |
-0.66 |
| FCF / Share |
-0.40 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
360,505 |
| Short Ratio |
0.72 |
| Short % of Float |
1.99% |
| Beta |
2.00 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
92.89 |
| PB Ratio |
6.45 |
| Revenue |
772,474 |
| Operating Income |
-11.20M |
| Net Income |
-11.19M |
| Free Cash Flow |
-8.15M |
| Net Cash |
-356,286 |
| Net Cash / Share |
-0.01 |
| Gross Margin |
84.30% |
| Operating Margin |
-1,449.92% |
| Profit Margin |
-1,448.90% |
| FCF Margin |
-1,054.65% |
| ROA |
-148.36% |
| ROE |
-1,182.64% |
| ROIC |
3,224.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$5.00*
(77.30% upside)
Low
4.00
Current: $2.82
High
6.00
Target: 5.00
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 0.66 | 1.17 | 1.81 | 4.97 | 3.01 | 6.27 | 1.13 | 0.08 | 0.60 | 0.62 |
| Revenue Growth | -43.74% | -35.41% | -63.58% | 64.99% | -51.98% | 454.99% | 1335.94% | -86.83% | -3.18% | - |
| Gross Profit | 0.65 | 1.07 | 1.81 | 4.91 | 3.01 | 4.69 | 0.80 | 0.08 | 0.60 | 0.62 |
| Operating Income | -10.96 | -10.85 | -13.88 | -10.15 | -18.44 | -27.63 | -38.44 | -27.99 | -24.10 | -12.68 |
| Net Income | -10.95 | -16.11 | 74.95 | -14.31 | -27.56 | -35.73 | -42.70 | -29.16 | 5.61 | -49.96 |
| Shares Outstanding | 14.39 | 8.53 | 8.08 | 7.77 | 7.56 | 7.44 | 6.09 | 4.95 | 4.53 | 4.04 |
| Earnings Per Share | -0.76 | -1.89 | 9.00 | -1.80 | -3.60 | -4.80 | -7.00 | -5.80 | 1.20 | -14.40 |
| Operating Cash Flow | -9.35 | 4.28 | 59.08 | 3.56 | -19.08 | -29.13 | -35.61 | -23.92 | -16.01 | -5.17 |
| Capital Expenditures | 0.03 | -0.05 | -0.03 | 0.04 | - | -1.11 | -1.24 | -0.66 | -0.18 | -0.37 |
| Free Cash Flow | -9.33 | 4.23 | 59.05 | 3.60 | -19.08 | -30.24 | -36.85 | -24.59 | -16.19 | -5.54 |
| Cash & Equivalents | 1.05 | 4.28 | 4.59 | 6.54 | 7.17 | 5.48 | 32.94 | 9.12 | 28.64 | 6.42 |
| Total Debt | 1.07 | 0.32 | 2.35 | 61.60 | 61.08 | 33.83 | 27.67 | 9.69 | 6.46 | 0.06 |
| Net Cash / Debt | -0.02 | 3.96 | 2.24 | -55.06 | -53.91 | -28.35 | 5.27 | -0.57 | 22.19 | 6.36 |
| Assets | 4.15 | 7.02 | 20.78 | 12.46 | 14.96 | 11.83 | 40.32 | 11.97 | 31.19 | 10.86 |
| Liabilities | 5.03 | 4.61 | 8.73 | 80.13 | 68.80 | 41.63 | 44.33 | 13.38 | 10.06 | 6.73 |
| Book Value | -1.61 | 1.74 | 11.38 | -68.14 | -54.31 | -29.80 | -4.01 | -1.41 | 21.13 | 4.13 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Navidea Biopharmaceuticals, Inc. |
| Country |
United States |
| Employees |
13 |
| CEO |
Jed Andrew Latkin |
Stock Information
| Ticker Symbol |
NAVB |
| Stock Exchange |
NYSE American |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NYSEAMERICAN: NAVB |
| IPO Date |
November 10, 1992 |
Description
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. In addition, the company offers NAV4694, a fluorine-18 labeled PET imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimer's disease and mild cognitive impairment. Further, the company is developing diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. Navidea Biopharmaceuticals, Inc. has a preclinical therapeutic research collaboration with IMV Inc. to explore the potential combinatory effect with their platform-based immunotherapies. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.